Document is current
Any future updates will be listed below
-
Authors
Generalova, Olga
Roy, Mohana http://orcid.org/0000-0002-9997-8935
Hall, Evan
Shah, Sumit A.
Cunanan, Kristen
Fardeen, Touran
Velazquez, Brianna
Chu, Gilbert
Bruzzone, Bianca
Cabot, Anna
Fisher, George A.
Srinivas, Sandy
Fan, Alice C.
Haraldsdottir, Sigurdis
Wakelee, Heather A.
Neal, Joel W.
Padda, Sukhmani K.
Johnson, Tyler
Heestand, Gregory M.
Hsieh, Robert W.
Ramchandran, Kavitha
-
Funding
Funding for this research was provided by:
Varian Medical Systems (VAFYZ)
- License Information
-
More Information
Article History
Received: 8 May 2021
Accepted: 26 August 2021
First Online: 15 September 2021
Declarations
:
: Obtained via institutional review board (IRB) at Stanford University, protocol number IRB-38423.
: Not applicable.
: Mohana Roy: Research Funding: Varian Medical Systems. Joel W. Neal: Honoraria: CME Matters, Clinical Care Options CME, Research to Practice CME, Medscape, Biomedical Learning Institute CME, Peerview, Prime Oncology CME, Projects in Knowledge CME, Rockpointe CME, MJH Life Sciences. Consulting or Advisory Role: AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda, Lilly, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron, NateraResearch Funding: Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar, Takeda, Adaptimmune, GlaxoSmithKline, Janssen. Sukhmani K. Padda: Research Funding: Epicentrx, Bayer, Boehringer Ingelheim; Advisory Boards: Blueprint, Astrazeneca, G1 Therapeutic, Pfizer, Janssen. Robert W. Hsieh: Employee and Shareholder in Genentech/Roche. Gregory M. Heestand: Spouse employment and stock ownership: Genentech/Roche, Consulting: Exelixis. Kavitha Ramchandran: Consulting Role: Groupwell, Research Funding: Varian Medical Systems. All other authors report no relevant conflicts of interests/competing interests/disclosures.
